Your session is about to expire
← Back to Search
Patiromer Oral Powder Product for Kidney Failure
Study Summary
This trial is testing whether a once-daily dose of patiromer will reduce the frequency of hyperkalemic episodes in ESRD patients receiving conventional hemodialysis.
- Kidney Failure
- Hyperkalemia
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the United States Food and Drug Administration (FDA) greenlighted Patiromer Oral Powder Product?
"The safety of Patiromer Oral Powder Product was assessed to be a 3, due to the fact it is in its fourth clinical trial phase and has already been approved."
What is the scope of participants in this research?
"This clinical trial is no longer seeking participants. It was initially announced on June 20th, 2019 and last updated June 10th, 2022. If you're searching for other studies related to hyperkalemia there are 601 active trials while Patiromer Oral Powder Product has 4 presently open studies."
Could you detail the prior research done on Patiromer Oral Powder Product?
"Presently, 4 Patiromer Oral Powder Product trials are still in progress with 2 of them at Phase 3. These studies take place in 25 disparate locations, most notably Durham, North carolina."
Is this research initiative open for registration at the moment?
"Unfortunately, according to clinicaltrials.gov this investigation is not presently enrolling patients; the trial was initially posted on June 20th 2019 and last updated on June 10th 2022. Nevertheless, there are 605 other active studies that may be seeking participants at this juncture."
Share this study with friends
Copy Link
Messenger